syngen
donor
ident
twin
sibl
autolog
recipi
donat
self
allogen
donat
materi
come
differ
individu
recipi
match
relat
partial
match
relat
donor
sibl
similar
human
leukocyt
antigen
hla
type
unrel
donor
match
unrel
donor
haploident
parent
cousin
sibl
child
donor
one
hla
haplotyp
match
cord
umbil
cord
blood
usual
partial
hla
match
match
blood
type
sometim
two
cord
use
provid
blood
suffici
cell
haplocord
haploident
peripher
blood
stem
cell
plu
cord
blood
cell
haplocord
engraft
rapidli
may
sustain
yet
provid
neutrophil
product
cord
engraft
peripher
blood
stem
cell
usual
filgrastim
granulocyt
colonystimul
factor
mobil
may
select
tcell
deplet
umbil
cord
blood
usual
associ
delay
engraft
less
graftversushost
diseas
gvhd
bone
marrow
collect
aspir
harvest
match
relat
match
unrel
donor
associ
less
chronic
gvhd
donor
lymphocyt
infus
donor
cell
sort
lymphocyt
given
engraft
relaps
antitumor
antivir
effect
stimul
gvhd
myeloabl
totalbodi
irradi
plu
cyclophosphamid
busulfan
without
irradi
nonmyeloabl
reduc
intens
use
lowerdos
totalbodi
irradi
antithymocyt
globulin
often
fludarabin
engraft
absolut
neutrophil
count
rise
day
primari
graft
failur
engraft
day
mix
chimer
persist
host
donor
hematopoiesi
relaps
return
underli
malign
condit
mucos
mucos
inflamm
serv
portal
entri
oral
intestin
infect
common
methotrexatecontain
regimen
palifermin
may
reduc
mucos
hemorrhag
cystiti
often
occur
conjunct
cyclophosphamid
earli
transplant
despit
use
mesna
forc
diuresi
viral
caus
common
later
transplant
includ
adenoviru
bk
viru
engraft
syndrom
immun
reconstitut
syndrom
fever
without
rash
andor
pulmonari
infiltr
engraft
venoocclus
diseas
also
call
sinusoid
obstruct
syndrom
triad
jaundic
weight
gain
ascit
lead
multiorgan
failur
usual
occur
first
week
transplant
diffus
alveolar
hemorrhag
bleed
alveoli
usual
second
third
week
transplant
diagnos
progress
bloodi
return
lung
lavag
treat
corticosteroid
graftversushost
diseas
inflamm
cell
death
apoptosi
skin
liver
gut
lung
acut
form
usual
occur
day
chronic
form
gener
occur
later
featur
resembl
distinct
scleroderma
risk
higher
elderli
graft
partial
match
donor
calcineurin
inhibitor
cyclosporin
tacrolimu
less
often
sirolimu
mycophenol
mofetil
start
soon
transplant
decreas
incid
sever
gvhd
highdos
corticosteroid
agent
use
treat
gvhd
posterior
revers
encephalopathi
syndrom
neurotox
hypertens
calcineurin
inhibitor
fludarabin
bronchiol
obliteran
organ
pneumonia
oblit
bronchiol
pneumon
associ
small
airway
injuri
sometim
associ
chronic
gvhd
acyclovir
low
dose
herp
simplex
viru
high
dose
cytomegaloviru
see
tabl
levofloxacin
use
prevent
bacteri
infect
fever
infect
develop
fluconazol
prevent
candidiasi
start
neutropenia
trimethoprimsulfamethoxazol
agent
choic
pneumocysti
also
cover
toxoplasma
bacteria
nocardia
altern
includ
aerosol
pentamidin
atovaquon
dapson
penicillin
vk
prevent
streptococcu
pneumonia
activ
chronic
gvhd
region
penicillin
resist
may
lead
use
levofloxacin
indic
voriconazol
posaconazol
given
place
fluconazol
prevent
mold
infect
echinocandin
micafungin
caspofungin
intraven
administ
agent
may
substitut
azol
lamivudin
prevent
hepat
b
viru
reactiv
antihepat
b
core
antibodyposit
hepat
b
surfac
antigenneg
hepat
b
dnaneg
patient
hepat
bposit
donor
entecavir
tenofovir
may
substitut
lamivudin
entecavir
tenofovir
prevent
hepat
b
viru
reactiv
hepat
b
surfac
antigenposit
patient
ivermectin
two
dose
patient
countri
high
risk
strongyloid
infest
ganciclovir
valganciclovir
foscarnet
given
patient
cytomegaloviru
reactiv
base
polymeras
chain
reaction
assay
blood
neutrophil
antigen
see
tabl
design
broadspectrum
agent
ceftazidim
piperacillintazobactam
cefepim
addit
aminoglycosid
possibl
requir
institut
antibiot
resist
pattern
vancomycin
cellul
dysfunct
indwel
cathet
hemodynam
instabl
colon
methicillinresist
staphylococcu
aureu
herp
simplex
viru
oral
esophag
vagin
ulcer
autoinoculaton
skin
site
varicellazost
viru
dermatom
zoster
may
dissemin
rare
sever
hepat
viscer
zoster
cytomegaloviru
fever
viremia
cytopenia
pneumon
gastrointestin
disord
eg
hepat
esophag
ulcer
mucos
chang
duodenum
colon
retin
prolong
neutropenia
gvhd
substanti
improv
support
care
sever
immunosuppress
patient
evolv
sinc
surviv
markedli
improv
time
outcom
transplant
improv
util
transplant
option
depend
less
avail
certain
donor
sourc
ie
whether
avail
match
donor
prior
decad
unrel
adult
volunt
donor
avail
half
gener
popul
unrel
umbil
cord
blood
use
increasingli
sourc
stem
cell
transplant
umbil
cord
blood
shown
effect
altern
patient
lack
suitabl
adult
donor
use
limit
find
umbil
cord
blood
unit
adequ
cell
dose
recipi
size
weight
strategi
transplant
two
close
match
ex
vivo
expand
umbil
cord
blood
unit
enabl
transplant
adult
condit
regimen
use
prepar
host
major
determin
outcom
variabl
host
tissu
injuri
potenti
induct
prolong
immunodefici
condit
regimen
may
includ
immunosuppress
cytotox
chemotherapi
alon
combin
widefield
totalbodi
irradi
condit
damag
mucos
surfac
facilit
transmucos
entri
bloodstream
infect
indwel
intraven
cathet
also
lead
dissemin
bloodstream
infect
environment
exposur
airborn
dust
fungal
spore
inocul
sinus
respiratori
tree
prophylact
antibiot
therapi
nutrit
chang
deplet
commens
potenti
protect
element
cutan
intestin
microbiom
infecti
risk
patient
undergo
hsct
affect
transplant
complic
includ
direct
effect
highdos
condit
mucos
hemorrhag
cystiti
diarrhea
hepat
venoocclus
diseas
vod
gvhd
relaps
underli
hematolog
oncolog
diseas
busulfan
melphalan
commonli
use
alkyl
agent
toxic
myeloid
stem
cell
mucos
epitheli
cell
cyclophosphamidecontain
regimen
predispos
patient
hemorrhag
cystiti
fludarabin
less
cytotox
intens
immunosuppress
often
includ
reducedintens
nonmyeloabl
condit
regimen
antithymocyt
globulin
alter
function
deplet
cell
lymphocyt
use
condit
regimen
aplast
anemia
time
gvhd
prevent
treatment
serum
sicknessa
syndrom
fever
arthralgia
rashcan
occur
antithymocyt
globulin
xenoprotein
therapi
treat
corticosteroid
therapi
antilymphoid
antibodi
includ
alemtuzumab
rituximab
induc
prolong
profound
lymphopenia
gvhd
prevent
strategi
includ
ex
vivo
graft
manipul
select
tlymphocyt
deplet
new
approach
posthsct
cyclophosphamid
day
graft
lyse
prolifer
alloreact
lymphoid
cell
cyclosporin
tacrolimu
mycophenol
mofetil
methotrex
sirolimu
agent
often
use
week
month
allograft
lessen
risk
sever
gvhd
although
may
reduc
risk
gvhd
maneuv
also
substanti
delay
immun
recoveri
particularli
haploident
one
hla
haplotyp
match
hlamismatch
hsct
clinic
approach
infect
patient
undergo
hematopoiet
stem
cell
transplant
hsct
involv
understand
basic
transplant
techniqu
clinic
syndrom
host
defens
defect
differ
time
transplant
natur
histori
individu
infect
mechan
underli
reconstitut
immun
system
transplant
gener
domin
element
infecti
risk
bacteri
viral
fungal
parasit
infect
hsct
depend
pretransplant
exposur
histori
viral
serostatu
whether
transplant
autolog
allogen
donor
sourc
number
day
transplant
consider
distinguish
determin
infecti
risk
autolog
allogen
graft
associ
risk
incur
ongo
immunosuppress
graftversushost
diseas
gvhd
therapi
differ
tempo
humor
cellular
immun
reconstitut
also
affect
risk
time
period
transplant
defin
era
differ
transplant
complic
evolut
slowli
resolv
posttransplant
immunodefici
cutan
mucos
barrier
breakdown
neutropenia
lymphopenia
hypogammaglobulinemia
combin
mani
posttransplant
complic
mimic
infecti
process
multipl
infect
may
occur
patient
time
therefor
patient
undergo
hsct
examin
context
pretransplant
infect
serolog
profil
document
infect
latenc
condit
regimen
avail
cultur
data
mucos
surfac
contemporan
transplant
complic
patient
institut
current
antimicrobi
prophylaxi
current
degre
durat
neutropenia
lymphopenia
hsct
involv
intraven
deliveri
hematopoiet
stem
cell
recipi
whose
hematopoiet
immun
system
ablat
alter
cytotox
immunosuppress
prepar
regimen
commonli
refer
condit
regimen
given
day
hsct
hematopoiet
stem
cell
obtain
bone
marrow
filgrastimstimul
peripher
blood
umbil
cord
blood
allogen
donor
relat
unrel
human
leukocyt
antigen
hla
match
loci
major
histocompat
complex
mismatch
hsct
option
treatment
disord
bone
marrow
failur
eg
aplast
anemia
fanconi
anemia
malign
eg
acut
chronic
leukemia
lymphoma
multipl
myeloma
hemoglobinopathi
thalassemia
sever
immunodefici
syndrom
inborn
error
metabol
eg
osteopetrosi
chronic
granulomat
diseas
hurler
syndrom
inherit
leukodystrophi
lysosom
disord
highrisk
solid
tumor
eg
neuroblastoma
germ
cell
tumor
current
use
investig
treatment
diseas
epidermolysi
bullosa
autoimmun
disord
scleroderma
allogen
transplant
feasibl
select
human
immunodefici
viru
hiv
posit
patient
malign
nonmalign
diseas
sinc
highli
activ
antiretrovir
therapi
becam
standard
treatment
hiv
infect
autolog
hsct
use
treatment
multipl
myeloma
neuroblastoma
certain
leukemia
lymphoma
morbid
mortal
aris
regimenrel
toxic
effect
earli
infect
allogen
hsct
use
diseas
list
previous
addit
hazard
higher
risk
graft
failur
infect
aspergillu
mold
lung
field
abnorm
sinus
toxoplasmosi
brain
lesion
high
despit
appropri
therapi
mucos
clear
oral
aliment
resum
oral
therapi
prefer
prophylaxi
hemorrhag
cystiti
common
complic
lead
gross
hematuria
clot
urinari
retent
impair
renal
function
cystiti
occur
within
first
week
marrow
infus
usual
noninfecti
origin
caus
instead
administr
highdos
cyclophosphamid
condit
regimen
prophylact
measur
includ
mesna
bind
elimin
alkyl
metabolit
cyclophosphamid
forc
diuresi
continu
bladder
irrig
support
care
establish
cystiti
may
also
necessit
largebor
cathet
drainag
bladder
irrig
transfus
later
posttransplant
period
gvhd
infect
contribut
caus
cystiti
major
infecti
agent
induc
cystiti
viral
usual
either
polyomaviru
bk
viru
adenoviru
infect
herp
simplex
viru
hsv
cytomegaloviru
cmv
polyomaviru
jc
viru
human
herpesviru
type
variou
bacteria
strongyloid
occur
lower
frequenc
use
fluoroquinolon
antibacteri
prophylaxi
may
prevent
bk
viruria
polyomavirus
shed
urin
mani
hsct
patient
without
clinic
symptom
see
chapter
higher
urin
detect
blood
viral
load
bk
viru
may
indic
higher
risk
hemorrhag
cystiti
standard
antivir
treatment
current
avail
viruria
caus
bk
viru
adenoviru
although
intravesicular
cidofovir
lowdos
intraven
cidofovir
administ
ongo
hemorrhag
larg
mucos
clot
persist
despit
continu
bladder
irrig
venoocclus
diseas
sinusoid
obstruct
syndrom
vod
syndrom
liver
toxic
occur
time
onset
highdos
condit
regimen
usual
day
character
pain
hepatomegali
weight
gain
hyperbilirubinemia
bilirubin
level
mgdl
sever
vod
sometim
call
sinusoid
obstruct
syndrom
mark
jaundic
ascit
lead
multiorgan
failur
involv
kidney
heart
lung
sometim
effect
anticoagul
antithrombolyt
therapi
initi
seriou
organ
failur
five
percent
patient
sever
vod
die
defibrotid
stabil
endothelium
limit
microvascular
thrombosi
effect
vod
definit
control
data
unavail
defibrotid
strong
promis
potent
new
treatment
option
clinic
predictor
sever
vod
includ
cytoreduct
therapi
high
dose
presenc
hepat
cytoreduct
therapi
persist
fever
cytoreduct
therapi
previou
radiat
therapi
liver
rare
presenc
schistosom
hepat
periport
fibrosi
condit
may
mimic
vod
includ
cholestasi
patient
septicemia
hepat
infiltr
secondari
infect
tumor
pericardi
tamponad
cytomegalovir
viral
hepat
intraabdomin
inflammatori
diseas
pancreat
periton
cholecyst
addit
earli
gvhd
cyclosporineinduc
cholestasi
noninfecti
caus
liver
toxic
may
coexist
mimic
vod
diagnosi
vod
may
difficult
ultrasonograph
assess
hepat
portal
venou
flow
may
definit
occas
liver
biopsi
immunohistochem
stain
cultur
rule
infecti
caus
may
indic
although
risk
hemorrhag
markedli
increas
hepatotox
nephrotox
drug
avoid
patient
vod
genet
polymorph
drug
metabol
may
modifi
risk
vod
clinic
predict
valu
uncertain
gvhd
major
lifethreaten
complic
develop
patient
allogen
transplant
risk
develop
gvhd
higher
older
patient
partial
match
unrel
donor
hsct
associ
higher
dose
irradi
totalbodi
irradi
may
administ
singl
dose
often
fraction
multipl
dose
given
sever
day
diarrhea
occur
virtual
treat
patient
first
week
irradi
may
treat
symptomat
stool
studi
pend
rule
infecti
caus
sever
oral
mucos
occur
mani
irradi
patient
aggrav
prolong
neutropenia
use
methotrex
gvhd
prophylaxi
long
bleed
oral
inflamm
compromis
patient
airway
mucos
treat
symptomat
keratinocyt
growth
factor
deliv
clinic
palifermin
proven
activ
prevent
oral
intestin
mucos
use
limit
mucos
may
benefit
patient
receiv
highli
toxic
condit
includ
highdos
totalbodi
irradi
highdos
melphalan
posthsct
methotrex
palifermin
shown
reduc
gvhd
infect
mortal
nonmyeloabl
transplant
reducedintens
nonmyeloabl
regimen
develop
goal
permit
donorderiv
hematopoiet
immunolog
reconstitut
lesserintens
regimen
may
provid
somewhat
weaker
anticanc
effect
reli
graftversustumor
effect
erad
underli
malign
dose
totalbodi
irradi
usual
gy
comparison
gy
fulli
abl
transplant
fludarabin
antithymocyt
globulin
lower
dose
cytotox
drug
may
use
induct
extend
immun
suppress
approach
often
use
older
patient
signific
medic
comorbid
condit
intens
immunosuppress
less
cytotox
result
less
mucos
enter
hepat
injuri
earli
week
transplant
yet
follow
similar
risk
gvhd
prolong
immunoincompet
gener
engraft
rapid
thu
neutropenia
briefest
patient
allogen
donor
complet
match
genet
hla
loci
often
consid
hlaa
b
c
similarli
ident
twin
syngen
transplant
hematopoiet
stem
cell
collect
recipi
autolog
use
lead
prompt
neutrophil
recoveri
allogen
hsct
highest
chanc
prompt
engraft
fulli
hlamatch
sibl
donor
transplant
use
fewer
intend
recipi
match
sibl
donor
avail
wellmatch
unrel
donor
umbil
cord
blood
partial
match
relat
donor
graft
also
suitabl
patient
greater
hla
mismatch
augment
risk
graft
failur
acut
chronic
gvhd
consequ
prolong
immunodefici
killer
immunoglobulinlik
receptor
kir
interact
hla
molecul
kir
ligand
bind
modul
function
natur
killer
nk
lymphoid
cell
hsct
alter
nkcell
function
may
modifi
risk
infect
gvhd
malign
relaps
kir
ligand
group
base
aminoacid
sequenc
determin
kirbind
epitop
primarili
hlac
hlab
molecul
owe
linkag
disequilibrium
inherit
coordin
hla
tcell
recoveri
nkcell
prolifer
function
matur
alter
kir
ligand
match
mismatch
statu
howev
recipi
stem
cell
unrel
donor
activ
nkcell
immunoglobulinlik
receptor
kir
bx
genotyp
decreas
infecti
complic
believ
due
enhanc
nkcell
function
role
kir
genotyp
donor
select
hsct
research
interest
time
prevent
strategi
includ
protect
isol
reduc
exposur
pathogen
enhanc
host
immun
reconstitut
hematopoiet
growth
factor
prophylaxi
highrisk
period
target
antimicrobi
chemotherapi
suppress
subclin
infect
preemptiv
therapi
best
facilit
schedul
period
surveil
prophylaxi
preemptiv
strategi
effect
treatment
infect
establish
mortal
rate
among
patient
establish
infect
continu
transplant
hbvinfect
donor
known
infect
transplant
high
hbv
viral
load
copiesml
import
risk
factor
clinic
appar
reactiv
recipi
posit
hbsag
among
recipi
pcr
studi
hbv
dna
yield
posit
result
persist
transplant
despit
treatment
risk
fatal
liver
diseas
may
hcvposit
donor
recipi
undergo
rna
viral
load
test
although
best
avoid
option
hcvinfect
individu
serv
donor
contrast
hbv
howev
rate
transmiss
hcv
hcv
rnaposit
donor
approach
interferon
use
suppress
hcv
replic
donor
limit
efficaci
system
hematolog
toxic
delay
respons
may
contain
activ
hcv
render
donor
suitabl
donat
expand
treatment
option
includ
proteas
inhibitor
therapi
may
use
drug
interact
calcineurin
inhibitor
may
issu
see
chapter
cellular
immun
system
must
function
hcv
produc
hepat
clinic
consequ
recogniz
recipi
earli
hsct
hcv
infect
increas
incid
vod
beyond
year
longterm
complic
hcv
infect
cirrhosi
data
demonstr
correl
hepat
c
genotyp
type
sever
liver
diseas
transplant
myelosuppress
effect
interferon
antivir
agent
use
treatment
hepat
c
hsct
limit
infecti
pneumonia
must
distinguish
noninfecti
pulmonari
complic
hsct
includ
pulmonari
edema
pleural
effus
alveolar
hemorrhag
radiat
injuri
pneumon
fibrosi
drug
reaction
adult
respiratori
distress
syndrom
idiopath
pneumonia
syndrom
cytolyt
thrombi
caus
multipl
peripher
lung
nodul
oblit
bronchiol
bronchiol
obliteran
organ
pneumonia
chronic
gvhd
manag
noninfecti
pneumonia
requir
lower
respiratori
tract
infect
rule
recognit
coexist
pathophysiolog
process
may
distinct
syndrom
may
like
respond
therapeut
highdos
corticosteroid
therapi
diffus
alveolar
hemorrhag
begin
dyspnea
alveolar
infiltr
distinguish
noninfecti
pneumonia
progress
bloodi
return
bronchoscop
examin
alveolar
lavag
syndrom
usual
occur
second
third
week
hsct
thrombocytopenia
rapid
neutrophil
recoveri
infect
toxic
effect
drug
radiat
intens
cytotox
regimen
solid
malign
implic
risk
factor
corticosteroid
recommend
improv
chanc
surviv
infrequ
idiopath
pneumonia
syndrom
process
widespread
alveolar
epitheli
injuri
character
clinic
diffus
interstiti
infiltr
vari
degre
respiratori
failur
absenc
activ
lower
respiratori
tract
infect
believ
relat
chemotherapi
totalbodi
irradi
use
part
condit
regimen
induc
proinflammatori
cytokin
releas
increas
alveolar
capillari
permeabl
idiopath
pneumonia
syndrom
occur
patient
may
frequent
allogen
autolog
transplant
thu
implic
least
anim
model
compon
graftversushost
reaction
mortal
rate
idiopath
pneumonia
syndrom
occur
classic
two
peak
one
first
week
second
third
month
transplant
corticosteroid
etanercept
may
yield
clinic
respons
diarrhea
diarrhea
transplant
primarili
result
noninfecti
caus
regimenrel
gut
mucos
toxic
gvhd
diarrhea
associ
infect
fewer
case
list
infecti
agent
respons
diarrhea
includ
clostridium
difficil
adenoviru
rotaviru
noroviru
enteroviru
coxsackieviru
donor
cell
infus
filgrastimmobil
peripher
blood
graft
acut
gvhd
donor
lymphocyt
mount
immun
attack
recipi
tissu
amplifi
proinflammatori
cytokin
favor
antineoplast
impact
accompani
gvhd
call
graftversusleukemia
gvl
effect
cell
possibl
nk
lymphoid
cell
mediat
gvl
effect
allogen
hsct
product
inflammatori
cytokin
direct
target
lysi
clinic
manifest
acut
gvhd
includ
rash
cholestat
hepat
nausea
vomit
diarrhea
effect
immunosuppress
agent
prevent
gvhd
includ
calcineurin
inhibitor
cyclosporin
tacrolimu
without
methotrex
mycophenol
mofetil
sirolimu
usual
start
transplant
gvhd
compound
prolong
posthsct
immunodefici
corticosteroid
immunosuppress
drug
use
treatment
gvhd
may
impair
phagocyt
function
directli
worsen
lymphopenia
cellular
immun
defici
patient
acut
chronic
gvhd
splenic
dysfunct
thu
ad
risk
infect
encapsul
bacteria
streptococcu
pneumonia
neisseria
meningitidi
haemophilu
influenza
tcell
deplet
donor
graft
less
associ
gvhd
cmv
aspergillu
infect
sometim
delay
immun
recoveri
clinic
hepat
hsct
recipi
rang
fever
accompani
abdomin
pain
fulmin
ill
infecti
hepat
must
distinguish
sever
common
noninfecti
caus
includ
liver
dysfunct
relat
condit
regimen
vod
acut
gvhd
cholestat
liver
injuri
relat
sepsi
chemic
hepat
relat
either
drug
hyperaliment
clinic
import
viral
hepat
syndrom
occur
transplant
includ
acquisit
reactiv
infect
hepat
b
viru
hbv
hepat
c
viru
hcv
varicellazost
viru
vzv
adenoviru
hsv
cmv
reactiv
hbv
like
hcv
result
fulmin
hepat
although
occur
minor
infect
patient
dissemin
vzv
adenoviru
infect
may
manifest
elev
serum
aminotransferas
level
elev
preced
appear
diseas
manifest
sever
day
rare
case
liver
biopsi
viral
cultur
polymeras
chain
reaction
pcr
assay
need
establish
diagnosi
sever
hepat
earli
postengraft
period
virus
hepat
g
viru
transfusiontransmit
virus
known
influenc
outcom
hsct
hbv
surfac
antigen
hbsag
surfac
antibodi
hbsab
core
antibodi
hbcab
hcv
serolog
profil
test
donor
recipi
hsct
pretransplant
imag
studi
liver
biopsi
may
need
evalu
hcvseroposit
patient
abnorm
liver
enzym
level
tender
hepatomegali
donor
recipi
posit
hbsag
test
viral
load
pcr
studi
hbv
dna
transplant
risk
hbv
hepat
reduc
treatment
lower
detect
viral
load
lamivudin
adefovir
tenofovir
commonli
use
suppress
hbv
replic
see
chapter
transplant
hbvinfect
donor
use
altern
donor
avail
intend
recipi
alreadi
seroposit
hbv
transmit
hbsagposit
less
like
hbcabposit
donor
recipi
either
hbv
hbsab
posit
hbcab
neg
risk
transmiss
low
hbvposit
donor
undetect
viral
load
recipi
hbv
transplant
subsequ
infect
like
clinic
consequ
transplant
delay
hbv
vaccin
recipi
use
hbv
immun
globulin
may
reduc
likelihood
hepat
transplant
hbv
immun
transfer
hbsabposit
donor
recipi
adopt
immun
transfer
hbv
infect
clear
hbsagposit
recipi
transplant
hbsabposit
ie
immun
donor
transplant
follow
recipi
monitor
period
pcr
test
hbv
dna
viral
load
liver
enzym
elev
suggest
activ
hbv
latenc
access
skincolon
organ
gastrointestin
mucos
flora
otherwis
steril
bodi
site
colon
vancomycinresist
enterococci
multidrugresist
pathogen
may
predispos
patient
bacteremia
recipi
autologoussyngen
allogen
graft
may
develop
similar
spectrum
infect
preengraft
period
major
transplantationrel
complic
occur
risk
period
mucos
sever
neutropenia
vod
similarli
frequent
type
transplant
howev
less
frequent
use
totalbodi
irradi
methotrex
rapid
neutrophil
recoveri
autolog
transplant
peripher
blood
stem
cell
markedli
decreas
risk
mucos
seriou
bacteremia
subpopul
patient
similarli
use
reducedintens
condit
regimen
nonmyeloabl
allograft
lessen
risk
earli
bacteremia
risk
period
hsv
predict
reactiv
patient
hsv
seroposit
infect
occur
week
transplant
prophylact
acyclovir
mg
twice
daili
mgkg
twice
daili
children
minim
clinic
infect
candidemia
earlyonset
aspergillosi
occur
fewer
patient
neutropenia
risk
greater
patient
slow
engraft
extend
neutropenia
transplant
fluconazol
mgday
voriconazol
micafungin
mg
iv
daili
prophylaxi
candida
albican
infect
mostli
elimin
risk
period
howev
candida
krusei
candida
glabrata
emerg
fluconazoleresist
pathogen
allogen
transplant
candid
higher
risk
mold
infect
preengraft
period
other
transplant
cours
begin
mold
prophylaxi
possibl
begin
even
week
hsct
patient
includ
extend
prehsct
neutropenia
acut
leukemia
undergon
serial
chemotherapi
transplant
myelodysplast
syndrom
aplast
fanconi
anemia
other
fungal
infect
occur
within
month
transplant
may
cure
could
reactiv
patient
remot
fungal
infect
receiv
standard
regimen
fungal
prophylaxi
patient
histori
aspergillosi
within
month
transplant
suspect
pulmonari
nodul
without
specif
diagnosi
receiv
secondari
fungal
chemoprophylaxi
ie
ongo
mainten
antifung
therapi
undergo
rescan
transplant
use
hematopoiet
growth
factor
reduc
incid
bacteremia
shorten
durat
neutropenia
agent
shown
improv
outcom
establish
infect
adjunct
therapi
granulocyt
transfus
use
center
treatment
seriou
infect
develop
patient
neutropenia
use
colonystimul
factor
dexamethason
prime
granulocyt
donor
increas
collect
yield
evalu
evid
efficaci
therefor
indic
use
expens
laborintens
support
measur
uncertain
still
studi
routin
cultur
hematopoiet
progenitor
cell
product
yield
low
rate
recoveri
bacteri
organ
often
corynebact
rium
spp
staphylococci
appropri
test
collect
graft
product
includ
routin
cultur
hematopoiet
progenitor
cell
hsct
patient
receiv
cultureposit
harvest
usual
without
clinic
advers
outcom
postengraft
risk
period
postengraft
period
begin
neutrophil
recoveri
continu
day
earli
band
tlymphocyt
function
recoveri
may
appar
reconstitut
lymphocyt
abnorm
function
approxim
month
evidenc
defici
vitro
antigen
mitogen
prolif
respons
howev
tlymphocyt
reconstitut
may
blunt
effect
gvhd
cmv
attend
treatment
corticosteroid
calcineurin
inhibitor
antitlymphocyt
therapi
ganciclovir
product
result
rate
infect
risk
period
higher
recipi
allogen
graft
like
develop
escherichia
coli
salmonella
giardia
strongyloid
cryptospo
ridium
campylobact
spp
infect
c
difficil
occur
increas
frequenc
outbreak
diarrhea
report
cryptosporidium
enteroviru
countri
report
diarrhea
associ
trichostrongylu
spp
typhliti
neutropen
enterocol
anaerob
infecti
syndrom
rel
common
may
associ
diarrhea
neutropenia
typhliti
preced
fever
abdomin
pain
right
lower
quadrant
tender
may
accompani
rebound
tender
append
mimic
typhliti
comput
tomographi
abdomen
reveal
rightsid
colon
enlarg
inflamm
thicken
mucosa
therapi
anaerob
bacteria
ad
medic
regimen
skin
erupt
often
noninfecti
occur
direct
result
radiat
effect
condit
therapi
secondari
gvhd
drug
allergi
rash
condit
regimen
result
sudden
onset
mark
erythema
larg
area
bodi
blister
hand
feet
skin
biopsi
assist
distinguish
infecti
noninfecti
caus
rash
lesion
suspect
infecti
sampl
submit
cultur
biopsi
common
infecti
caus
vzv
catheterrel
exit
site
tunnel
infect
cutan
manifest
dissemin
bacteri
fungal
infect
focal
area
bacteri
cellul
may
occur
lower
extrem
set
edema
heart
failur
vod
lymphedema
impair
venou
return
osteomyel
uncommon
hsct
spectrum
organ
includ
atyp
mycobacteria
yeast
mold
addit
bacteria
rare
instanc
osteomyel
follow
marrow
aspir
sternum
marrow
harvest
iliac
crest
prolong
pain
fever
occur
bone
marrow
harvest
osteomyel
caus
staphylococcu
aureu
consid
histor
three
risk
period
immunolog
defici
occur
predict
graft
recipi
hsct
fig
preengraft
period
earli
postengraft
period
day
late
postengraft
period
day
understand
immun
defici
risk
period
period
peak
risk
individu
infect
observ
standard
infect
prophylaxi
help
clinician
recogn
uncommon
manifest
infecti
pathogen
tabl
preengraft
risk
period
begin
onset
condit
therapi
continu
approxim
day
transplant
definit
graft
failur
declar
neutrophil
recoveri
day
pretransplant
neutropenia
associ
increas
infectionrel
mortal
bacteri
infect
common
time
profound
neutropenia
lymphopenia
necessit
prophylact
promptli
administ
empir
system
antibiot
therapi
see
chapter
prophylact
system
antibiot
often
fluoroquinolon
levofloxacin
administ
neutrophil
count
drop
less
continu
neutrophil
count
recov
prevent
bacteri
infect
see
chapter
gastrointestin
decontamin
nonabsorb
antibiot
use
past
rare
perform
prophylact
antibiot
use
shift
spectrum
gastrointestin
microbiota
potenti
pathogen
organ
c
difficil
enterococci
etiolog
agent
bacteremia
shift
gramposit
organ
particular
coagulaseneg
staphylococci
enterococci
viridansgroup
streptococci
often
isol
bloodstream
cultur
febril
neutropen
hsct
recipi
mechan
barrier
defect
caus
mucos
central
cathet
predispos
patient
bloodstream
infect
allow
filament
mold
effect
prophylaxi
deep
mycos
patient
high
risk
care
surveil
requir
highrisk
group
serum
galactomannan
screen
insuffici
sensit
reliabl
earli
detect
aspergillu
infect
although
infrequ
infect
agent
mucormycosi
may
occur
resist
advanc
azol
eg
voriconazol
prophylaxi
pneumocysti
jirovecii
infect
trimethoprimsulfamethoxazol
tmpsmx
dapson
atovaquon
aerosol
gvhd
cmv
recipi
autologoussyngen
graft
anoth
consequ
gvhd
risk
period
disrupt
gastrointestin
mucosa
permit
transmur
entri
pathogen
lead
bacteremia
fungemia
lateonset
aspergillosi
may
also
occur
risk
period
patient
especi
continu
gvhd
receiv
highdos
corticosteroid
poor
graft
function
advancedgener
azol
activ
patient
longer
take
immunosuppress
medic
remain
free
gvhd
patient
continu
chronic
gvhd
period
persist
long
therapi
chronic
gvhd
requir
includ
dysfunct
lymphocyt
macrophag
humor
immun
vzv
reactiv
infect
encapsul
bacteria
pneumonia
n
meningitidi
h
influenza
invas
aspergillosi
invas
tissu
mold
infect
may
develop
late
risk
period
malign
diseas
relaps
regardless
tempo
choic
therapi
impair
restor
immunocompet
surviv
relaps
may
lengthi
indol
malign
eg
chronic
myelogen
leukemia
chronic
lymphocyt
leukemia
follicular
lymphoma
posthsct
immunodefici
persist
therefor
even
relaps
ongo
surveil
therapi
posthsct
patient
remiss
still
requir
common
clinic
infect
syndrom
includ
sinus
bronchiti
pneumonia
otiti
media
caus
respiratori
virus
bacteria
cmv
diseas
may
develop
therefor
cmv
surveil
must
continu
seroposit
recipi
chronic
gvhd
pentamidin
requir
month
chronic
gvhd
continu
longer
reactiv
cmv
predict
occur
patient
cmv
seroposit
transmiss
seroneg
recipi
seroposit
donor
uncommon
surveil
reactiv
cmv
improv
use
schedul
cmv
test
either
antigenemia
assay
pcr
test
serum
dna
ganciclovir
antivir
therapi
initi
preemptiv
subclin
indic
reactiv
reduc
incid
endorgan
diseas
caus
cmv
seroposit
recipi
continu
gvhd
delay
immun
recoveri
partial
matchedor
unrelateddonor
hsct
lead
lateronset
cmv
infect
may
indic
need
prolong
cmv
surveil
late
posttransplant
risk
period
begin
approxim
day
end
patient
regain
normal
immun
month
hsct
gener
clinic
immun
recoveri
demonstr
end
first
year
transplant
long
natur
histori
individu
infect
occur
hsct
recipi
may
distinct
immunocompromis
patient
popul
infect
occur
high
incid
among
hsct
recipi
justifi
prophylaxi
applic
risk
period
empir
treatment
cours
infect
see
tabl
gramposit
organ
account
half
bacteremia
occur
hsct
although
skin
believ
primari
reservoir
organ
colon
gastrointestin
tract
may
addit
sourc
staphylococcu
epidermidi
ie
coagulaseneg
staphylococcu
speci
commonli
recov
cultur
skin
nose
oropharyng
organ
includ
streptococcu
pyogen
streptococcu
miti
enterococcu
spp
vancomycinsensit
vancomycinresist
speci
unlik
catheterassoci
infect
aureu
candida
spp
gramneg
bacilli
gramposit
bacteremia
manag
success
without
remov
intravascular
devic
methicillinresist
aureu
mrsa
rare
neutropen
infect
becom
frequent
patient
respond
initi
antibiot
manag
tender
erythema
along
cathet
tunnel
tract
cathet
remov
rare
case
adjunct
surgic
skin
tunnel
need
cathet
remov
surgic
often
requir
tunnel
infect
caus
rapidli
grow
mycobacteria
gramneg
organ
second
frequent
caus
bloodstream
infect
incid
infect
pseudomona
spp
low
part
use
antipseudomon
antibiot
prophylaxi
initi
empir
therapi
neutropen
fever
howev
virul
potenti
sepsi
syndrom
remain
high
gramneg
organ
includ
e
coli
klebsiella
spp
enterobact
spp
pseudomona
spp
although
bacteremia
histor
occur
neutropen
period
bacteremia
continu
develop
patient
longterm
central
intraven
cathet
patient
ongo
immunosuppress
result
gvhd
therapi
neutropenia
secondari
graft
failur
drugrel
marrow
suppress
eg
ganciclovir
patient
experi
chronic
gvhd
otherwis
asplen
risk
lifethreaten
bacteri
sepsi
encapsul
organ
increas
invas
pneumococc
infect
may
occur
month
year
hsct
annual
incid
per
allogen
hsct
recipi
higher
per
among
chronic
gvhd
penicillin
macrolid
prophylaxi
may
indic
immunosuppress
discontinu
report
frequent
penicillinresist
pneumococc
infect
gener
popul
prompt
chang
prophylaxi
penicillin
quinolon
center
viridansgroup
streptococc
bacteremia
mostli
caus
miti
may
carri
high
mortal
rate
earli
hsct
poor
dental
hygien
risk
factor
miti
bacteremia
hsct
patient
normal
antibiot
sensit
organ
may
resist
norfloxacin
ciprofloxacin
penicillin
patient
receiv
prophylact
antibiot
vancomycin
drug
choic
hsct
patient
oral
ulcer
caus
hsv
reactiv
condit
believ
entri
point
corrobor
decreas
incid
viridansgroup
streptococc
septicemia
activ
prophylaxi
hsv
infect
acyclovir
mycobacteria
infrequ
caus
infect
hsct
import
identifi
treatment
requir
medic
would
use
empir
rapidli
grow
nontubercul
mycobacteria
respons
cathet
exit
site
infect
tunnel
infect
bacteremia
waterborn
mycobacterium
muco
genicum
pneumonia
infect
mycobacterium
tuber
culosi
occur
predominantli
countri
high
endem
rate
late
infect
may
common
among
patient
unrel
donor
among
patient
whose
donor
famili
member
even
absenc
gvhd
approxim
late
pneumonia
patient
ongo
chronic
gvhd
caus
noninfecti
interstiti
pneumon
lung
histopatholog
studi
reveal
organ
oblit
bronchiti
may
respond
corticosteroid
therapi
nonmyeloabl
hsct
associ
less
disrupt
mucos
barrier
shorter
period
sever
neutropenia
fewer
episod
bacteremia
first
day
trend
toward
fewer
episod
bacteremia
first
day
hsct
howev
type
transplant
still
associ
sever
gvhd
often
necessit
highdos
corticosteroid
treatment
often
use
older
patient
compromis
organ
function
poor
perform
statu
gvhd
cmv
diseas
invas
fungal
infect
may
delay
month
overal
incid
condit
similar
convent
myeloabl
hsct
first
year
hsct
patient
undergo
nonmyeloabl
hsct
may
need
surveil
cmv
fungal
infect
well
beyond
day
well
preemptiv
prophylact
treatment
similar
myeloabl
hsct
recipi
day
year
hsct
protect
measur
discuss
hsct
reinforc
recoveri
period
involv
travel
crowd
pet
regard
travel
particular
restrict
strategi
minim
transmiss
infecti
diseas
summar
social
situat
sit
crowd
movi
theater
classroom
may
increas
risk
acquir
viral
respiratori
ill
turn
away
individu
cough
sneez
even
quickli
don
mask
may
help
prevent
transmiss
airborn
dropletbas
infect
patient
need
instruct
rememb
augment
infect
prevent
wash
hand
soon
possibl
close
someon
cold
outbreak
norovirus
involv
cruis
ship
type
outbreak
eg
staphylococcu
commonli
associ
close
live
quarter
type
vacat
cruis
ship
may
unwis
vacat
choic
healthi
dog
cat
consid
accept
pet
howev
immunosuppress
patient
get
new
pet
respons
scoop
cat
litter
potenti
toxoplasma
cyst
exposur
similarli
patient
play
sandbox
area
concentr
site
outdoor
cat
may
use
litter
box
reptil
mani
sort
report
infect
salmonella
patient
touch
anim
aquarium
home
water
tropic
fish
tank
may
carri
myco
bacterium
marinum
chlamydia
psittaci
transmit
psittacin
bird
hand
wash
use
alcoholbas
hand
rub
disinfect
mainstay
infect
prevent
hospit
clinic
person
enter
patient
room
perform
examin
touch
patient
includ
visitor
well
health
care
worker
wash
disinfect
hand
outsid
room
respiratori
viru
season
infect
control
personnel
often
add
extra
signag
doorway
place
ward
remind
visitor
import
hand
wash
staff
visitor
respiratori
viral
infect
permit
direct
contact
patient
routin
use
gown
glove
mask
combin
requir
presenc
neutropen
transplant
recipi
ongo
caution
prevent
interperson
nosocomi
transmiss
essenti
advanc
infect
prevent
strategi
risk
period
infect
chang
import
understand
among
hsvseroposit
recipi
first
month
transplant
incid
hsv
reactiv
reduc
less
use
acyclovir
valacyclovir
initi
time
condit
continu
mucos
heal
major
postengraft
hsv
infect
confin
oropharynx
although
infect
occasion
extend
directli
squamou
epitheli
surfac
upper
esophagu
larynx
skin
perior
perian
area
patient
respond
acyclovir
engraft
particularli
receiv
prolong
repeat
cours
acyclovir
may
acyclovirresist
hsv
foscarnet
cidofovir
may
benefici
set
uncommon
case
hsv
infect
caus
bell
palsi
hepat
enceph
valacyclovir
achiev
predict
higher
drug
level
acyclovir
oral
administr
histor
incid
rate
primari
cmv
infect
among
cmvseroneg
hsct
recipi
reduc
less
use
cmvsafe
blood
product
transfus
cellular
graft
associ
cmv
transmiss
cmvseroneg
recipi
receiv
cmvseroposit
donor
graft
incid
cmv
reactiv
viremia
tradit
cmvseroposit
patient
allogen
transplant
among
patient
autolog
transplant
reduc
use
preemptiv
prophylact
antivir
therapi
common
approach
prophylact
acyclovir
combin
preemptiv
earli
ganciclovir
product
therapi
median
time
onset
cmv
endorgan
diseas
delay
month
toward
month
hsct
indic
cmv
surveil
must
longer
group
high
risk
see
chapter
weekli
screen
enabl
identif
patient
might
benefit
preemptiv
therapi
ganciclovir
product
tabl
cmv
leukocyt
antigen
quantit
dna
pcr
test
excel
method
earli
cmv
detect
although
antigen
test
unreli
neutropenia
cmv
identifi
earli
detect
method
patient
treat
day
induct
ganciclovir
therapi
mgkg
intraven
twice
daili
follow
mainten
therapi
ganciclovir
mgkg
intraven
daili
valganciclovir
mg
oral
daili
sever
week
beyond
neg
cmv
test
result
tabl
mainten
therapi
may
need
continu
patient
persist
detect
viru
profound
immunosuppress
caus
activ
gvhd
oral
valganciclovir
safe
effect
ganciclovir
prodrug
valin
ester
cleav
first
pass
liver
consid
patient
need
induct
andor
longterm
mainten
otherwis
take
oral
medic
without
difficulti
valganciclovir
dosag
mg
per
day
produc
bloodlevel
drug
exposur
similar
produc
intraven
mgkg
dose
ganciclovir
foscarnet
use
empir
patient
marrow
suppress
ganciclovir
fail
respond
ganciclovir
concurr
viremia
foscarnet
administ
dose
mgkg
intraven
everi
hour
induct
mgkg
intraven
everi
hour
mainten
good
urin
number
case
may
increas
worldwid
transplant
becom
avail
global
transplant
candid
donor
risk
reactiv
latent
tuberculosi
readili
identifi
pretransplant
evalu
basi
resid
endem
area
close
contact
anoth
person
known
suspect
tuberculosi
transplant
candid
screen
recommend
tuberculin
skin
test
ex
vivo
releas
assay
quantiferontb
gold
clinic
signific
infect
prevent
extendeddur
antitubercul
prophylaxi
quantiferontb
gold
assay
reactiv
tuberculin
skin
test
yield
posit
result
potenti
transplant
patient
donor
also
receiv
screen
histori
abnorm
chest
radiograph
find
hsct
recent
travel
foreign
countri
longer
month
employ
institut
tubercul
client
histori
alcohol
intraven
drug
use
seroposit
human
immunodefici
viru
hiv
quantiferontb
gold
specif
unaffect
vaccin
bacillu
patient
posit
result
screen
test
sign
activ
tuberculosi
previou
antitubercul
therapi
chest
radiograph
liver
function
studi
obtain
addit
peritransplant
posttransplant
therapi
isoniazid
pyridoxin
legionellosi
nocardiosi
uncommon
manifest
pneumonia
lung
nodul
hsct
patient
detect
legionella
direct
fluoresc
antibodi
dfa
assay
prove
unreli
hsct
set
falseposit
result
detect
high
proport
diseas
caus
legionella
speci
speci
includ
legionella
feeleii
legionella
micdadei
legionella
bozemana
infect
persist
relaps
week
appropri
antimicrobi
therapi
suggest
prolong
antibiot
treatment
indic
hsct
recipi
legionellosi
medic
therapi
nocardiosi
often
consist
administr
sulfonamid
combin
synergist
agent
ceftazidim
imipenemcilastatin
adjunct
surgic
may
use
catheterrel
infect
organ
role
intracellular
bacteri
agent
pathogen
well
defin
listeria
monocytogen
infect
may
manifest
bacteremia
mening
certain
viral
infect
prevent
administr
acyclovir
hsvseroposit
patient
preengraft
period
wide
accept
cmvsafe
serolog
screen
filter
blood
product
transfus
cmvseroneg
patient
prove
effect
prevent
transfusionacquir
cmv
infect
period
eg
weekli
cmv
diagnost
surveil
cmvseroposit
patient
postengraft
period
prompt
institut
antivir
therapi
essenti
cmvseroneg
patient
seroneg
allogen
donor
compar
low
risk
therefor
diagnost
monitor
continu
week
scrupul
hand
wash
avoid
crowd
prevent
transmiss
respiratori
viral
infect
hospit
ambulatori
clinic
remain
mainstay
effect
infect
control
practic
hsct
recipi
patient
receiv
ganciclovir
preemptiv
therapi
first
day
among
patient
cmv
pneumon
mortal
rate
high
even
prompt
antivir
treatment
combin
intraven
immun
globulin
ivig
cmvspecif
immun
globulin
cmv
viremia
pneumon
rare
engraft
anorexia
nausea
vomit
sometim
diarrhea
character
cmv
gastroenter
diagnosi
made
endoscopi
biopsi
immunoperoxidas
stain
cmvinfect
cell
cmv
diseas
gastrointestin
tract
often
associ
gvhd
specif
organ
respons
therapi
ensur
even
ganciclovir
cmv
gastrointestin
diseas
strongli
associ
increas
nonrelaps
mortal
although
cmv
retin
common
among
patient
infect
hiv
quit
uncommon
among
hsct
recipi
end
organ
establish
diseas
cmv
infect
difficult
treat
cmv
pneumon
treat
combin
ganciclovir
induct
dose
day
ivig
mgkg
everi
day
durat
induct
day
mainten
ganciclovir
standard
ivig
gener
use
cmvspecif
immun
globulin
scarc
costli
shown
improv
outcom
cmv
enter
treat
ganciclovir
induct
dose
week
longer
treatment
protract
cmv
enter
might
includ
ganciclovir
longer
durat
ganciclovir
mainten
therapi
facilit
gastrointestin
heal
develop
cmvspecif
cytotox
tlymphocyt
respons
critic
reconstitut
normal
immun
protect
late
cmv
diseas
longterm
ivig
delay
recoveri
cmv
immun
patient
remain
risk
late
diseas
cmv
monitor
continu
beyond
day
patient
treat
acyclovir
follow
ganciclovir
treat
serial
ganciclovir
cours
may
increas
risk
develop
genotyp
resist
clinic
resist
episod
treat
foscarnet
cidofovir
genotyp
assay
mutat
gene
abl
confirm
virolog
resist
extend
ganciclovir
therapi
appear
delay
recoveri
cytotox
tlymphocyt
activ
either
direct
effect
lymphocyt
limit
amount
antigen
exposur
lymphocyt
immunodefici
revers
cytotox
lymphocyt
given
adopt
technolog
avail
tertiari
center
vzv
infect
primari
occurr
occurr
reactiv
patient
time
first
year
transplant
vzv
effect
prevent
acyclovir
prophylaxi
vzv
prophylaxi
employ
transplant
center
adult
patient
pediatr
patient
develop
infect
first
year
transplant
median
time
onset
month
transplant
prolong
antivir
prophylaxi
may
delay
onset
vzv
associ
rebound
vzv
local
zoster
may
manifest
atyp
vesicl
skin
lesion
may
appear
atyp
vesicl
therefor
laboratori
confirm
vzv
reactiv
recommend
manifest
vzv
diseas
often
dermatom
shingl
may
includ
hemorrhag
pneumonia
hepat
abdomin
pain
central
nervou
system
diseas
thrombocytopenia
retin
necrosi
dissemin
viscer
varicelliform
zoster
may
manifest
low
back
pain
acut
abdomin
pain
appear
skin
lesion
gvhd
strong
predispos
factor
vzv
dissemin
involv
viscer
organ
patient
fatal
case
dissemin
abdomin
zoster
occur
patient
treat
suboptim
dose
acyclovir
therapi
initi
rel
late
cours
infect
highdos
acyclovir
mgkg
iv
everi
hour
treatment
choic
dissemin
vzv
infect
valacyclovir
famciclovir
use
stepdown
treatment
intraven
acyclovir
initi
treatment
local
infect
although
uncommon
patient
alreadi
seroposit
may
acquir
second
primari
vzv
infect
vzv
vaccin
recommend
anniversari
visit
patient
free
immunosuppress
medic
flow
minim
irrit
urethra
labia
foscarnet
serum
biochem
abnorm
chelat
calcium
phosphat
accompani
foscarnet
therapi
necessit
hospit
observ
care
electrolyt
monitor
least
initi
day
use
endorgan
manifest
cmv
diseas
includ
pneumon
enter
rare
case
retin
cmv
pneumon
occur
fewer
cmvseroposit
allogen
type
infrequ
progress
pneumonia
prophylact
earli
initi
oseltamivir
therapi
upper
respiratori
tract
diseas
may
prevent
progress
lower
respiratori
tract
diseas
respiratori
syncyti
viru
parainfluenza
associ
high
incid
progress
upper
lower
tract
diseas
among
infect
patient
upper
respiratori
tract
ill
parainfluenza
usual
resolv
without
seriou
sequela
lower
tract
infect
mortal
rate
respiratori
syncyti
viru
parainfluenza
viru
therapi
aerosol
ribavirin
combin
ribavirin
ivig
use
respiratori
syncyti
viru
although
rigor
trial
determin
efficaci
avail
surviv
rate
appear
higher
treatment
initi
signific
hypoxia
present
aerosol
ribavirin
may
help
decreas
viral
burden
anecdot
case
report
regard
effect
ribavirin
treatment
respiratori
virus
includ
parainfluenza
adenoviru
influenza
preemptiv
therapi
aerosol
ribavirin
patient
posit
nasopharyng
cultur
respiratori
syncyti
viru
appear
promis
patient
develop
respiratori
viral
pneumonia
engraft
poorer
outcom
aerosol
ribavirin
virazol
administ
face
mask
adult
smallparticl
aerosol
gener
devic
use
patient
ventil
although
data
dose
may
effect
g
one
vial
per
hour
daili
schedul
use
contamin
patient
room
possibl
teratogen
agent
concern
pregnant
hospit
staff
see
chapter
prevent
exposur
critic
treatment
effect
protect
involv
use
frequent
hand
wash
hospit
staff
droplet
isol
patient
cold
respiratori
tract
symptom
addit
famili
member
health
care
worker
upper
respiratori
tract
symptom
separ
patient
vaccin
famili
member
health
care
worker
close
contact
influenza
may
help
control
exposur
amantadin
rimantadin
prophylaxi
limit
use
widespread
develop
resist
oseltamivir
provid
use
prophylaxi
influenza
b
appear
use
use
hous
facil
hsct
recipi
immun
globulin
prophylaxi
respiratori
syncyti
virusspecif
polyclon
monoclon
antibodi
use
infant
high
risk
suffici
evalu
hsct
set
respiratori
viru
season
patient
respiratori
symptom
sampl
taken
nasopharynx
evalu
respiratori
virus
major
epsteinbarr
viru
ebv
reactiv
subclin
requir
therapi
incid
ebvrel
complic
may
higher
among
recipi
umbil
cord
blood
transplant
receiv
antitcel
serotherapi
antithymocyt
globulin
alemtuzumab
among
recipi
hlamatch
unrelateddonor
marrow
myeloabl
transplant
hlamismatch
especi
haploident
tcelldeplet
graft
may
lead
prolong
tcell
lymphopenia
augment
risk
ebv
reactiv
quantit
diagnost
monitor
ebv
viral
load
accompani
preemptiv
therapi
may
reduc
risk
progress
lifethreaten
posttransplant
lymphoprolif
disord
ptld
case
high
viral
load
associ
progress
ptld
infus
rituximab
nonirradi
donor
leukocyt
may
effect
treatment
allograft
recipi
hightit
ebv
viremia
ptld
human
herpesviru
implic
possibl
caus
bone
marrow
suppress
fatal
meningoenceph
interstiti
pneumon
fewer
hsct
patient
recipi
umbil
cord
blood
may
viremia
popul
appear
reactiv
commonli
occur
hsct
patient
accord
cultur
diagnosi
mani
patient
accord
pcr
assay
blood
mani
episod
reactiv
detect
dna
pcr
may
asymptomat
valu
therapi
subclin
viremia
henc
surveil
unknown
highlevel
sever
month
unless
underli
hematolog
oncolog
diseas
relaps
vaccin
use
lowerplaqueform
unit
version
varivax
use
prevent
chickenpox
among
children
highertit
zostavax
vaccin
use
immunocompet
older
adult
vzv
fastidi
viru
may
withstand
time
requir
transport
specimen
diagnost
laboratori
scrape
base
vesicl
examin
cell
dfa
vzvspecif
monoclon
antibodi
clinician
best
diagnos
lesion
herp
zoster
chickenpox
tzanck
smear
less
sensit
longer
recommend
tissu
diagnosi
made
histolog
examin
immunohistochem
techniqu
cultur
pcr
assay
avail
laboratori
techniqu
choic
vzvseroneg
patient
receiv
signific
exposur
person
activ
incub
chickenpox
cours
acyclovir
without
varicellazost
immun
globulin
varizig
recommend
prevent
chickenpox
see
chapter
acyclovir
usual
treatment
dose
mgkg
intraven
everi
hour
day
exposur
seem
appropri
vzvseroposit
patient
live
dwell
someon
index
case
activ
chickenpox
shingl
acyclovir
report
use
prevent
new
infect
varizig
usual
given
expos
seroposit
patient
antivir
prophylaxi
often
recommend
depend
exposur
length
time
sinc
transplant
level
immunosuppress
lowerrisk
patient
valacyclovir
g
oral
three
time
daili
may
appropri
although
efficaci
situat
unknown
patient
alreadi
receiv
empir
ganciclovir
cmv
reactiv
need
antivir
agent
adenoviru
infect
reactiv
approxim
allogen
approxim
autolog
adult
hsct
patient
chronic
shed
occur
absenc
clinic
diseas
adenoviru
also
acquir
respiratori
droplet
transmiss
common
clinic
manifest
set
adenoviru
caus
hemorrhag
cystiti
system
infect
lung
liver
gastrointestin
tract
kidney
occur
infect
patient
gvhd
risk
factor
occurr
clinic
appar
adenoviru
infect
hsct
addit
allogen
patient
receiv
ganciclovir
seroneg
cmv
seroposit
without
need
ganciclovir
higher
risk
develop
adenoviru
infect
patient
receiv
ganciclovir
even
though
ganciclovir
activ
adenoviru
immunofluoresc
shell
vial
convent
tube
cultur
blood
urin
stool
tissu
use
diagnos
adenoviru
pcr
test
help
diagnosi
infect
gener
costeffect
surveil
mani
patient
asymptomat
center
use
quantit
viral
load
monitor
follow
preemptiv
treatment
lowdos
mgkg
cidofovir
three
time
week
center
may
access
adenovirusspecif
cytotox
cell
effect
therapi
avail
adenovir
infect
although
cidofovir
lipidconjug
deriv
use
patient
abl
toler
potenti
toxic
patient
undergon
hsct
develop
respiratori
viral
infect
typic
present
rhinorrhea
nasal
congest
may
also
fever
cough
throat
pain
headach
myalgia
common
pathogen
patient
includ
respiratori
syncyti
viru
parainfluenza
viru
lesser
extent
influenza
viru
rhinoviru
human
metapneumoviru
coronaviru
current
rapid
test
method
allow
detect
respiratori
syncyti
viru
parainfluenza
influenza
virus
respiratori
specimen
within
hour
see
chapter
respiratori
viru
infect
commonli
occur
winter
season
caus
pneumonia
patient
although
progress
lower
tract
infect
less
common
nonmyeloabl
condit
regimen
contrast
parainfluenza
viru
type
infect
may
occur
throughout
year
nosocomi
outbreak
respiratori
syncyti
viru
occur
time
establish
winter
season
influenza
often
aspergillu
mold
infect
acquir
exogen
inhal
spore
respiratori
tract
environ
local
may
occur
higher
frequenc
summer
common
site
initi
infect
includ
lung
sinus
although
contigu
hematogen
extens
central
nervou
system
intern
organ
may
occur
use
fluconazol
prophylaxi
preengraft
period
invas
aspergillosi
emerg
lead
fungal
infect
found
autopsi
among
patient
underw
hsct
preengraft
prophylaxi
moldact
therapi
use
patient
may
aspergillu
incub
time
transplant
owe
prior
infect
prolong
neutropenia
postengraft
prophylaxi
posaconazol
voriconazol
led
decreas
mortal
among
patient
high
risk
invas
aspergillosi
incid
invas
aspergillosi
among
patient
undergo
hsct
rang
onset
aspergillu
infect
hsct
occur
bimod
distribut
first
peak
week
neutropenia
second
month
hsct
usual
conjunct
persist
gvhd
postengraft
aspergillosi
occur
month
alongsid
chronic
gvhd
also
cmv
older
age
associ
acquisit
aspergillosi
either
preengraft
postengraft
risk
period
donor
type
male
gender
summer
season
recogn
risk
factor
preengraft
aspergillosi
wherea
construct
vicin
hospit
gvhd
attend
corticosteroid
therapi
lymphopenia
cmv
respiratori
viru
infect
multipl
myeloma
signific
risk
factor
develop
postengraft
aspergillosi
earli
aspergillosi
tempor
associ
neutropenia
therefor
infect
among
autolog
hsct
patient
rare
engraft
estim
surviv
rate
among
patient
proven
invas
aspergillosi
although
aggress
prolong
combin
antifung
therapi
may
improv
outcom
prevent
strategi
focu
reduc
environment
host
risk
factor
use
higheffici
particul
air
hepa
filter
air
system
laminar
airflow
room
preengraft
risk
period
aid
prevent
infect
particularli
allograft
recipi
hepa
filter
capabl
remov
particl
greater
diamet
mold
spore
patient
room
continu
maintain
posit
pressur
relat
corridor
enhanc
barrier
effect
transport
hepafilt
room
discharg
tightfit
face
mask
reproduc
barrier
sometim
use
least
earli
posthsct
period
patient
might
ask
whether
portabl
hepa
filter
purchas
use
hospit
extra
measur
implement
individu
basi
unit
obtain
room
patient
occupi
day
night
unit
size
room
place
evid
clinic
efficaci
filter
hospit
set
prevent
acquisit
airborn
mold
infect
outpati
probabl
littl
valu
consider
expens
prevent
strategi
includ
nasal
aerosol
amphotericin
b
studi
control
trial
avail
accur
earli
diagnost
test
invas
fungal
infect
lag
behind
type
infect
aspergil
lu
galactomannan
test
use
patient
alreadi
take
antifung
therapi
includ
coverag
mold
minor
highrisk
allogen
recipi
antigenand
nucleic
acidbas
diagnost
test
studi
earli
diagnosi
invas
tissu
mold
infect
demonstr
use
clinic
practic
test
larg
number
clinic
sampl
hsct
recipi
blood
cultur
mold
rare
yield
posit
find
mold
organ
except
case
fusarium
high
index
suspicion
persist
febril
neutropen
patient
time
comput
tomographi
chest
detect
new
infiltr
import
earli
detect
invas
pulmonari
aspergillosi
small
groundglass
halo
around
lung
lesion
pleurabas
nodular
infiltr
comput
tomograph
scan
viremia
associ
acut
gvhd
nonrelaps
mortal
strain
identifi
hsct
appear
caus
b
variant
blood
urin
although
variant
correl
pneumon
greater
dna
homolog
cmv
treatment
document
infect
usual
initi
induct
dose
foscarnet
respons
antivir
therapi
univers
benefit
antivir
therapi
rigor
determin
parvoviru
hpv
rare
caus
refractori
anemia
erythroid
hypoplasia
hsct
antibodi
pcr
test
detect
parvoviru
although
pcr
assay
may
yield
posit
find
month
acut
infect
use
singlepati
room
hsct
ward
may
prevent
transmiss
contagi
viru
patient
undergo
hsct
administr
ivig
reason
may
treat
subclin
infect
see
chapter
invas
fungal
infect
import
caus
morbid
mortal
major
caus
invas
fungal
diseas
includ
candida
spp
aspergillu
spp
less
frequent
nonaspergillu
filament
mold
patient
undergo
allogen
transplant
increas
risk
invas
fungal
infect
comparison
patient
receiv
autolog
graft
system
fluconazol
prophylaxi
lowdos
amphotericin
b
mgkg
daili
decreas
incid
system
candidiasi
advancedgener
azol
micafungin
prophylaxi
extend
spectrum
organ
cover
includ
mold
gener
valu
costeffect
allograft
recipi
shown
empir
therapi
febril
neutropen
patient
discuss
chapter
p
jirovecii
infect
usual
manifest
pneumonia
dyspnea
cough
fever
bilater
infiltr
major
infect
patient
occur
autolog
allogen
transplant
although
frequenc
lower
former
use
routin
prophylaxi
pneumocysti
infect
occur
approxim
patient
underw
allogen
hsct
median
month
transplant
associ
risk
death
prophylaxi
tmpsmx
result
neglig
rate
infect
patient
toler
medic
contain
sulfa
prophylaxi
option
includ
desensit
tmpsmx
use
dapson
atovaquon
inhal
pentamidin
treatment
choic
p
jirovecii
infect
tmpsmx
candida
candidiasi
infect
acquir
endogen
organ
colon
gastrointestin
tract
usual
manifest
fungemia
viscer
candidiasi
see
chapter
fluconazol
prophylaxi
onset
candidiasi
occur
median
week
transplant
candida
spp
second
frequenc
asper
gillu
spp
caus
brain
abscess
hsct
current
cumul
incid
rate
invas
candidiasi
first
year
hsct
probabl
less
risk
factor
invas
candidiasi
includ
neutropenia
breakdown
normal
mucos
barrier
use
broadspectrum
antibiot
corticosteroid
c
albi
can
infect
success
prevent
fluconazol
given
prophylaxi
time
condit
either
engraft
day
hsct
strategi
prolong
fluconazol
therapi
associ
improv
surviv
rate
although
mechan
observ
benefit
uncertain
benefit
fluconazol
prophylaxi
less
clear
autolog
transplant
degre
mucos
less
use
fluconazol
sinc
number
candida
infect
decreas
spectrum
colon
infect
candida
organ
shift
c
albican
candida
tropicali
includ
c
krusei
c
glabrata
candida
parapsilosi
c
krusei
innat
resist
fluconazol
associ
neutrophil
recoveri
addit
antifung
therapi
case
fusari
endophthalm
enucl
affect
eye
may
requir
mucormycosi
uncommon
hsct
mimic
aspergillosi
clinic
may
occur
long
hsct
caus
one
hepat
infect
includ
overthecount
herbal
medic
patient
receiv
voriconazol
prophylaxi
risk
breakthrough
infect
invas
mucormycosi
risk
breakthrough
infect
appear
low
posaconazol
may
effect
mainten
treatment
infect
caus
certain
speci
mucoral
respons
amphotericin
b
clinic
signific
infect
caus
dimorph
fungi
includ
coccidioidomycosi
histoplasmosi
blastomycosi
unusu
even
hyperendem
area
unit
state
parasit
infect
hsct
usual
manifest
reactiv
toxoplasmosi
although
chaga
diseas
malaria
strongyloidiasi
schistosomiasi
clonorchi
infect
giardiasi
cryptosporidiosi
pulmonari
microsporidiosi
acan
thamoeba
trichomona
meningoenceph
also
report
routin
blood
smear
hsct
use
rule
malari
transmiss
hong
kong
clonorchi
sinensi
infect
identifi
screen
stool
examin
perform
day
hsct
none
patient
symptom
relat
clonorchiasi
patient
receiv
praziquantel
mgkg
oral
three
time
day
hsct
subsequ
stool
examin
reveal
presenc
ova
toxoplasmosi
infrequ
hsct
occur
patient
seroposit
transplant
although
parasit
transmit
primari
infect
marrow
blood
product
donor
solid
organ
toxoplasmosi
patient
undergon
hsct
almost
alway
result
reactiv
prior
infect
gvhd
risk
factor
suppress
cellmedi
immun
critic
host
defens
toxoplasma
gondii
clinic
present
includ
fever
enceph
focal
cerebr
lesion
pneumon
myocard
one
postmortem
diagnosi
dissemin
toxoplasmosi
associ
hemophagocyt
syndrom
parasitemia
featur
reactiv
may
identifi
tissu
cultur
although
mani
diagnos
made
pcr
countri
preval
infect
high
pretranspl
detect
dna
use
pcr
may
indic
highest
risk
infect
transplant
stereotact
brain
biopsi
also
use
diagnosi
infect
identifi
risk
period
week
hsct
toxoplasmosi
common
among
receiv
myeloabl
condit
seroposit
patient
receiv
tmpsmx
risk
breakthrough
toxoplasmosi
patient
toxoplasma
reactiv
monitor
pcr
assay
first
month
hsct
howev
countri
preval
low
routin
prophylaxi
justifi
patient
undergo
autolog
allogen
hsct
eventu
lose
immun
common
childhood
diseas
serial
reimmun
month
transplant
tabl
see
fig
efficaci
vaccin
influenc
time
elaps
sinc
transplant
natur
hematopoiet
graft
presenc
gvhd
use
serial
immun
report
exacerb
gvhd
immun
patient
underw
hsct
nation
survey
hsct
immun
practic
reveal
vaccin
underutil
schedul
revaccin
vari
ensur
complianc
recommend
transplant
recipi
immun
schedul
regardless
cell
sourc
indic
nonliv
vaccin
administ
patient
undergon
hsct
regardless
transplant
type
presenc
gvhd
patient
revaccin
everi
year
combin
tetanusdiphtheriapertussi
toxoid
absorb
highli
suggest
aspergillosi
mold
infect
neutropen
host
bronchoscopi
cytolog
examin
cultur
lavag
fluid
fungi
well
organ
common
immunocompromis
host
import
galactomannan
assay
bronchoalveolar
lavag
fluid
may
augment
diagnost
valu
lack
clinic
radiograph
respons
empir
antifung
therapi
may
necessit
tissu
sampl
minim
invas
surgeri
videoassist
thoracoscop
surgeri
associ
less
morbid
openlung
biopsi
patient
undergon
hsct
suspect
invas
mold
infect
promptli
begin
take
moldact
antifung
agent
diagnost
procedur
arrang
advancedgener
azol
agent
echinocandin
less
nephrotox
lipid
prepar
amphotericin
b
lack
clinic
radiograph
respons
proven
infect
may
necessit
switch
agent
differ
class
combin
therapi
combin
treatment
fungal
infect
echinocandin
azol
polyen
agent
common
wherea
result
larg
random
clinic
trial
fail
show
benefit
echinocandin
agent
may
fungistat
rather
fungicid
case
mold
infect
interrupt
cell
wall
synthesi
limit
activ
grow
hypha
document
invas
tissu
mold
infect
therapi
usual
continu
week
lesion
resolv
stabl
immunocompet
improv
patient
afebril
although
amphotericin
b
gold
standard
antifung
agent
sinc
voriconazol
produc
superior
outcom
treatment
aspergillosi
patient
contrast
patient
treat
amphotericin
b
follow
antifung
therapi
treatment
central
nervou
system
mold
infect
includ
voriconazol
basi
patient
studi
attain
cerebrospin
fluid
level
approxim
plasma
level
central
nervou
system
tissu
level
approxim
plasma
level
see
chapter
initi
control
aspergillu
infect
subsequ
mainten
therapi
durat
immunosuppress
advoc
reduc
risk
reactiv
multipl
drugdrug
interact
occur
azol
adjust
may
requir
immunosuppress
agent
transient
visual
disturb
hallucin
occur
voriconazol
difficulti
achiev
therapeut
plasma
drug
level
complic
administr
itraconazol
posaconazol
itraconazol
solut
improv
oral
bioavail
capsul
use
although
blood
level
monitor
may
need
ensur
adequ
absorpt
posaconazol
good
antimold
activ
oral
absorpt
requir
high
fat
intak
may
feasibl
patient
gvhd
enter
complic
malassezia
furfur
caus
tinea
versicolor
catheterrel
fungemia
sometim
pneumonia
respons
either
topic
system
therapi
slow
recoveri
granulocyt
count
usual
associ
resolut
cathet
remov
discontinu
intraven
lipid
import
success
outcom
case
fungemia
trichosporonosi
manifest
fungemia
skin
lesion
pneumon
arthriti
fungemia
usual
acquir
via
intraven
cathet
report
trichosporon
rhodo
torula
spp
cryptococcu
laurentii
hansenula
anomala
mening
cryptococcu
neoforman
unusu
contrast
frequent
occurr
among
patient
infect
hiv
widespread
anticandida
prophylaxi
fluconazol
may
contribut
low
frequenc
infect
nonaspergillu
mold
alternaria
pseudallescheria
scedosporium
paecilomyc
fusarium
phialophora
spp
infrequ
caus
invas
tissu
infect
whose
clinic
appear
similar
aspergillu
infect
indistinguish
aspergillu
hypha
tissu
section
thu
cultur
requir
identif
dissemin
fusariosi
fatal
infect
patient
undergon
hsct
manifest
posit
blood
cultur
skin
lesion
endophthalm
success
resolut
usual
transplant
recipi
chronic
liver
diseas
includ
hepat
c
infect
chronic
gvhd
live
hepat
aendem
area
area
experienc
outbreak
given
hepat
vaccin
requir
two
dose
given
month
apart
transplant
recipi
potenti
occup
exposur
rabi
preexposur
rabi
vaccin
delay
least
month
month
hsct
major
defect
humor
immun
absenc
specif
antibodi
product
antibodi
level
first
year
hsct
affect
primarili
pretransplant
level
recipi
lesser
degre
donor
among
patient
chronic
gvhd
reduc
product
opson
antibodi
class
immunoglobulin
g
immunoglobulin
antibodi
seen
immunodefici
complic
poor
splenic
function
associ
risk
recurr
pneumococc
infect
episod
bronchiti
pneumonia
ivig
prevent
infect
given
weekli
preengraft
late
risk
period
reduc
rate
septicemia
local
infect
given
postengraft
risk
period
transplant
may
modul
sever
gvhd
replac
ivig
mgkg
everi
week
may
benefici
patient
immunoglobulin
g
level
lower
mgdl
howev
one
prospect
trial
routin
use
ivig
delay
recoveri
antigen
viral
specif
immun
role
hyperimmun
globulin
prevent
specif
infect
less
clear
hightit
cmv
globulin
prevent
cmv
infect
treatment
endorgan
cmv
diseas
prove
clear
benefit
comparison
ivig
howev
antivir
drug
effect
provid
protect
cmv
diseas
therefor
limit
avail
well
cost
consider
use
cmvspecif
globulin
minim
transplant
center
hyperimmun
respiratori
syncyti
viru
globulin
provid
modest
increas
neutral
antibodi
given
first
week
hsct
hepat
b
human
rabi
tetanu
immun
globulin
use
need
event
exposur
varizig
human
polyclon
immunoglobulin
g
avail
intramuscular
intraven
administr
expand
access
program
cangen
corpor
patient
high
risk
within
first
day
exposur
varizig
administr
may
extend
varicella
incub
period
day
much
day
expens
uniformli
effect
prevent
chickenpox
patient
undergon
hsct
vaccin
acellular
pertussi
gener
enough
immun
vaccin
higherdos
pertussi
toxoid
use
transplant
recipi
studi
month
also
immun
polio
inactiv
intramuscular
vaccin
h
influenza
type
b
hepat
b
pneumonia
patient
previous
immun
one
dose
hepat
b
vaccin
given
postvaccin
titer
hepat
b
viru
document
ensur
respons
adequ
protect
even
vaccin
given
specifi
time
interv
hsct
year
second
dose
pneumococc
vaccin
option
provid
second
opportun
vaccin
person
fail
respond
first
dose
especi
patient
chronic
gvhd
lifelong
season
administr
influenza
vaccin
begin
hsct
resum
month
hsct
children
younger
year
receiv
influenza
vaccin
first
time
requir
two
dose
yearli
adult
benefit
receiv
two
influenza
vaccin
dose
influenza
vaccin
hsct
ward
employe
clinic
health
care
worker
household
contact
may
especi
necessari
within
first
year
patient
ongo
gvhd
protect
respons
may
impair
health
care
worker
directli
care
hsct
recipi
live
attenu
intranas
vaccin
avoid
limit
inadvert
exposur
patient
vaccin
quadrival
human
papillomaviru
vaccin
studi
may
appropri
male
femal
longterm
transplant
recipi
age
year
perhap
women
older
age
risk
squamou
intraepitheli
lesion
live
viru
vaccin
measlesmumpsrubella
varicella
given
transplant
recipi
activ
gvhd
ongo
immunosuppress
therapi
first
dose
given
transplant
recipi
month
hsct
take
immunosuppress
medic
presum
immunocompet
second
measlesmumpsrubella
dose
given
month
later
howev
benefit
second
dose
popul
evalu
vaccin
liveattenu
vzv
vaccin
varivax
zostavax
use
vzvseroneg
patient
longer
requir
immunosuppress
therapi
free
gvhd
varicella
vaccin
given
person
older
year
two
dose
given
week
apart
requir
vaccin
hsct
recipi
develop
reactiv
shingl
transplant
need
suscept
famili
member
receiv
vzv
vaccin
minim
chickenpox
exposur
vzvseroneg
transplant
recipi
routin
administr
hepat
meningococc
rabi
vaccin
indic
hepat
vaccin
recommend
